Table 3.
Frequency of anti-SAE occurrence in different myositis groups.
| Western cohorts | Asian cohorts | ||||||
|---|---|---|---|---|---|---|---|
| Study | Betteridge | Tarricone | Betteridge | Bodoki | Fujimoto | Muro | Our study |
| [3] | [5] | [4] | [8] | [6] | [7, 9] | ||
| IIM | 44 | 130 | 266 | 337 | 518 | 150 | 570 |
| Adult DM | 2/20 (10%) | 5/75 (7%) | 11/131 (8%) | 4/73 (5%) | 6/445 (1%) | 7/138 (5%) | 12/394 (3%) |
| PM | 0/24 | 0/43 | 0/124 | 0/211 | 0/62 | 0 | 0/144 |
| JDM | 0 | 0/12 | NA | 0/17 | 1/11 | 0/12 | 0/32 |
| F/M | 1/1 | NA | 7/4 | 2/2 | 4/3 | 3/4 | 9/3 |
| Heliotrope sign | 2/2 (100%) | 2/5 (40%) | 9/11 (82%) | 3/4 (75%) | 4/7 (57%) | 3/7 (43%) | 9/12 (75%) |
| V sign | 2/2 (100%) | NA | 3/7 (43%) | 1/4 (25%) | 4/7 (57%) | 5/7 (71%) | 6/12 (50%) |
| Shawl sign | 2/2 (100) | NA | 3/7 (43%) | 1/4 (25%) | 6/7 (86%) | 4/7 (57%) | 6/12 (50%) |
| Gottron’s sign | 2/2 (100%) | 5/5 (100%) | 9/11 (82%) | 3/4 (75%) | 6/7 (86%) | 7/7 (100%) | 9/12 (75%) |
| Muscular weakness | 0/2 (0) | 5/5 (100%) | 11/11 (100%) | 4/4 (100%) | 6/7 (86%) | 5/7 (71%) | 8/12 (67%) |
| Periungal changes | 2/2 (100%) | 1/5 (20%) | 8/8 (100%) | 1/4 (25%) | 5/5 (100%) | 5/6 (83%) | NA |
| Arthralgia | NA | 0/4 (0) | 2/11 (18%) | 2/4 (50%) | 1/7 (14%) | 0/7 (0) | 4/11936%) |
| Elevated CK | 2/2 (100%) | 4/5 (80%) | 9/11 (82%) | NA | 5/7 (71%) | 7/7 (100%) | 6/11 (55%) |
| Dysphagia | 2/2 (100%) | 0/5 (0) | 7/9 (78%) | 3/4 (75%) | 2/7 (29%) | 3/7 (43%) | 7/11 (64%) |
| ILD | 2/2 (100%) | 0/5 (0) | 2/11 (18%) | 1/4 (25%) | 5/7 (71%) | 5/7 (71%) | 7/11 (64%) |
| Cancer | 0/2 (0) | 1/5 (20%) | 2/11 (18%) | 1/4 (25%) | 1/7 (14%) | 4/7 (57%) | 2/11 (18%) |